Adjunctive EVX-101 is anticipated to be effective in many patients suffering from anxiety disorders, OCD, PTSD, and other psychiatric disorders where SSRI or SNRI therapy alone is often insufficient.
Clinical science suggests that adjunctive treatment with EVX-101 to ongoing SSRI/SNRI therapy would produce weight loss in obese patients.
Low brain serotonin is a risk-factor for suicide. Conversely, elevating brain serotonin can mitigate suicide-related behaviors in humans and animals. EVX-101 will elevate brain serotonin. EVX-101 is therefore a putative drug treatment for suicide prevention in vulnerable individuals.